Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis

Elsa M. Ronde¹ | Charlotte M. Heidsma¹ | Anne M. Eskes¹ | Josefine E. Schopman² | Elisabeth J. M. Nieveen van Dijkum¹

¹Department of Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
²Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Abstract

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are often diagnosed in an advanced stage. As the optimal sequence of therapy remains largely unclear, all treatment-related outcomes, including health-related quality of life (HRQoL) prospects, should be assessed according to patients’ preferences.

Methods: A targeted search was performed in PubMed and EMBASE to identify studies on treatment effect and HRQoL, measured using the EORTC QLQ-C30 tool, in patients with advanced, well-differentiated GEPNENs. Study quality was assessed, and meta-analyses were performed for global health status/QOL and tumour response.

Results: The search yielded 1,322 records, and 20 studies were included, examining somatostatin analogues (SSA), peptide receptor radionuclide therapies (PRRT), chemotherapy, SSA-based combination therapies, and targeted therapies. Global HRQoL was stable, and rates for disease stabilisation were moderate to high across all treatments. Meta-analyses for global health status/QOL after SSA treatment were not significant (mean difference: −0.3 [95% CI: −1.3 to 0.7]). The highest pooled overall tumour response rate was 33% (95% CI: 24–45%) for PRRT. The highest pooled clinical benefit rate was 94% (95% CI: 65–99%) for chemotherapy.

Conclusion: All treatments appeared beneficial for disease stabilisation while maintaining stable global health status/QOL. High-quality HRQoL reporting was lacking. HRQoL should be a central outcome next to well-established outcomes.

Keywords
adverse drug events, neoplasms, neuroendocrine tumour, quality of life, treatment, treatment outcome
1 | INTRODUCTION

Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous neoplasms, originating from neuroendocrine cells in the gastrointestinal tract (Fraenkel et al., 2012; Öberg et al., 2012). Most GEPNENs are nonfunctioning neoplasms, and half of patients present with advanced disease (Hallet et al., 2015; Pavel, O’Toole, et al., 2016).

Patients with GEPNENs generally have lower HRQoL compared to the general population, due the symptoms associated with functioning tumours as well as treatment-related symptoms and adverse events (AEs) (Beaumont et al., 2012; Haugland et al., 2009; Swinburn et al., 2012). However, the life expectancy of patients with advanced disease may be several years (Dasari et al., 2017), and higher HRQoL has been shown to be associated with longer survival (Coates et al., 1997). Therefore, it is essential to explore treatment options that maintain or improve patients’ HRQoL whilst extending progression-free survival (PFS).

Surgical resection with curative intent remains the preferred treatment whenever possible (Delle Fave et al., 2016; Niederle et al., 2016; Pavel, O’Toole, et al., 2016; Ramage et al., 2016). However, advanced and unresectable disease requires other treatment strategies to improve survival and maintain health-related quality of life (HRQoL). Somatostatin analogues (SSA) are currently the first-line treatment of metastatic GEPNENs (Falconi et al., 2016; Pavel, O’Toole, et al., 2016). Second- and third-line therapies include chemotherapy, targeted therapy and peptide receptor radionuclide therapy (PRRT) (Pavel, O’Toole, et al., 2016). However, the optimal sequence of therapy after first-line treatment still needs to be determined (Pavel, O’Toole, et al., 2016).

When several possible treatment options are considered, patients’ preferences should play a decisive role during treatment-related shared decision-making (Oshima Lee & Emanuel, 2013). Shared decision-making involves weighing the benefits and harms of treatment options against patients’ opinions and preferences (Stiggelbout et al., 2012). Therefore, clinicians need easy access to up-to-date evidence on the advantages and disadvantages of available treatment options. Moreover, the evidence needs to be comprehensive, that is, include all or nearly all important outcomes, as patients may favour HRQoL prospects over prolonged survival (Shrestha et al., 2019).

Previous systematic reviews have described HRQoL and oncological outcomes of treatments separately (Jiménez-Fonseca et al., 2015; Watson et al., 2020). However, to our knowledge, no publication has reported the effects of treatments on survival, tumour regression, adverse events and HRQoL together. This systematic review and meta-analysis is the first to summarise the overall effects of various treatment strategies in patients with GEPNENs, focusing on the validated European Organisation for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) questionnaire.

2 | METHODS

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Moher et al., 2009). A systematic literature search was conducted in PubMed and EMBASE in July 2019 and was updated in June 2020 and June 2021, to identify publications on treatment effect, including HRQoL, in patients with well-differentiated GEPNENs. The search strategies were constructed with the help of a clinical librarian. A combination of free text and controlled vocabulary were included, using key-words such as neuroendocrine tumour, treatment outcome, and quality of life. The words “tumour” and “neoplasm” were both used in combination with words describing tumour type (e.g., “endocrine” or “neuroendocrine”) and location (e.g., “pancreatic” and “duodenal”). The search was limited to full text publications in English. No restriction was placed on publication date. Reference lists of eligible articles were manually screened to identify additional relevant articles. A sample of our search is available in the Supporting Information.

Duplicates were removed prior to study selection. Two reviewers (ER, CH) screened all titles and abstracts against the eligibility criteria. Subsequently, full-texts of selected articles were screened for

| TABLE 1 | PICO table with inclusion and exclusion criteria |
|----------------|-----------------------------------------------|
| **PICO**       | **Inclusion criteria**                      | **Exclusion criteria**                      |
| Patients       | ≥18 years of age                            | <18 years of age                           |
|                | Well-differentiated                          | Poorly differentiated GEPNENs              |
|                | GEPNENs                                      | Neuroendocrine carcinomas                  |
|                |                                              | Primary tumour located outside of the gastroenteropancreatic tract |
| Intervention   | Any treatment of the primary tumour          | Selective treatment of (liver) metastases |
|                |                                              | Treatment focused on adverse effect        |
|                |                                              | alleviation (no expected anti-tumour effect) |
| Comparison     | Any comparator (or none)                     | -                                            |
| Outcome        | HRQoL measured using the EORTC QLQ-C30      | Other HRQoL questionnaires                |
|                | (preferably with GINET21 module)             |                                              |
|                | Treatment effect outcomes (e.g., tumour response, survival, adverse events) | |

*Inclusion of less than 1% of poorly differentiated grade 3 NENs or non-GEPNENs was accepted due to the assumption of negligible influence on study results.
inclusion. A third reviewer (END) was consulted in the case of disagreement.

An overview of the in- and exclusion criteria are shown in Table 1. Inclusion criteria were (1) patients ≥18 years of age with histologically well-differentiated GEPNENs (Lloyd et al., 2017), (2) interventions focused on treating the primary tumour, and (3) treatment effect outcomes including HRQoL, measured using the EORTC QLQ-C30 questionnaire with or without the NEN-specific QLQ-GINET21 module (Davies et al., 2006; Yadegarfar et al., 2013). This questionnaire is the most frequently used questionnaire in this patient population (Jimenez-Fonseca et al., 2015; Martini et al., 2016; Watson et al., 2020). As the present review aimed to compare treatments directly, we limited study eligibility to the QLQ-C30 and the NEN-specific module, in order to minimise heterogeneity and maximise comparability. Other outcomes of interest were treatment efficacy outcomes (e.g., tumour response and survival) and adverse events. Cross-sectional studies, reviews, letters and editorials were not eligible for inclusion.

The following data were extracted using a pre-defined form: study characteristics, patient characteristics, tumour type, tumour grade according to the World Health Organization (WHO) classification (Lloyd et al., 2017), presence of metastases and outcome data. Primary outcomes were EORTC QLQ-C30 and GINET21 scores, PFS and overall survival (OS). A change of ≥10 points in HRQoL scores was considered clinically significant, which corresponds to a change reported as “moderate” (10–20 points) or “very much” (>20 points) by patients (Osoba et al., 1998; Osoba et al., 2000). The EORTC QLQ-C30 summary score was calculated if sufficient data was available, according to the EORTC scoring manual (Scoring of the QLQ-C30 Summary Score, 2018).

Secondary outcomes were overall response rate (ORR), clinical benefit (CB) and AEs, reported using a validated scale. ORR was defined as the proportion of patients with minor, partial or complete radiological response, CB was defined as the proportion of patients with radiological response (ORR) or radiological stable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and the WHO solid tumour response criteria (Eisenhauer et al., 2009; Miller et al., 1981).

A risk of bias assessment for individual studies was performed by one reviewer (ER) using the Cochrane Risk of Bias tool for randomised-controlled trials (RCT) (Higgins et al., 2011) and the Newcastle Ottawa Scale (NOS) (Wells et al., 2013) for cohort or case-control studies. The other reviewers were consulted in case of any uncertainty. The Cochrane tool evaluates risk of bias as “low,” “high” or “unclear” in 6 domains: selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias. The NOS awards a maximum of nine stars for study quality in three categories: selection (4 stars), comparability (2 stars) and exposure or outcome (3 stars), for case-control and cohort studies, respectively. The overall score is used to categorise overall study quality as high (>7 stars), moderate (5–7 stars) or low (<5 stars). Risk of bias across studies was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Handbook, rating evidence as high, moderate, low or very low quality (Schunemann et al., 2013).

Meta-analyses were performed using R for Mac version 4.0.2 via the R-studio interface, to investigate the unstandardized mean difference of HRQoL scales and to investigate the overall ORR and CB results for each treatment category (RCordTeam, 2020). A random effects model with inverse variance weighting was used to pool these results due to expected heterogeneity. The I² statistic was used to measure the proportion of variance due to differences in studies, where 0% implied homogeneity and 100% heterogeneity. If the I² statistic was >75%, heterogeneity was considerable, and the results were unsuitable for meta-analysis. Pooled global HRQoL results are presented as mean difference with a 95% confidence interval (CI). Pooled ORR and CB results were presented as proportions with their 95% CI. Finally, results were summarised into a table that can be used as guide for treatment planning and informing patients about treatment options.

3 RESULTS

The systematic search and cross-referencing identified 1,322 records after removal of duplicates. A review of titles and abstracts excluded 917 records. Subsequently, 407 full-text articles were assessed for eligibility, and 20 were included (Arnold et al., 2005; Caplin et al., 2014; Cwikla et al., 2010; Delpassand et al., 2014; Ducrœux et al., 2014; Faivre et al., 2017; Fazio et al., 2021; Mitry et al., 2014; Pavel, Unger, et al., 2016; Phan et al., 2016; Ramage et al., 2019; Rinke et al., 2009, 2017, 2019; Strosberg et al., 2017, 2018, 2020; Vinik et al., 2016). The study selection process is shown in Figure 1. Five publications reported further results of previously published studies: two published long-term survival results (Faivre et al., 2017; Rinke et al., 2017); one reported tumour response outcomes of the CLARINET trial (Phan et al., 2016); one published HRQoL results from the NETTER-1 trial (Strosberg et al., 2018); and one published updated efficacy and safety results (Fazio et al., 2021). Furthermore, two publications reported post-hoc HRQoL analyses (Rinke et al., 2019; Vinik et al., 2016) and one reported on the impact of liver tumour burden in the NETTER-1 trial (Strosberg et al., 2020). These studies were analysed in combination with the original publication. In summary, 20 publications reporting on 12 study populations and 1,256 patients with well-differentiated GEPNENs were included. Out of these 12 study populations, five were randomised-controlled trials (RCT) (Arnold et al., 2005; Caplin et al., 2014; Raymond et al., 2011; Rinke et al., 2009; Strosberg et al., 2017), and seven were cohort populations (Cwikla et al., 2010; Delpassand et al., 2014; Ducrœux et al., 2014; Mitry et al., 2014; Pavel, Unger, et al., 2016; Ramage et al., 2019; Raymond et al., 2018). The included studies reported on the SSAs...
octreotide or lanreotide (Caplin et al., 2014; Rinke et al., 2009), the PRRTs $^{90}$Y-DOTATATE or $^{177}$Lu-DOTATATE (Cwikla et al., 2010; Delpassand et al., 2014), the chemotherapy modalities bevacizumab and capecitabine (Mitry et al., 2014) or bevacizumab combined with 5-fluorouracil and streptozocin (Ducreux et al., 2014), the targeted therapies sunitinib or everolimus (Pavel, Unger, et al., 2016; Ramage et al., 2019; Raymond et al., 2011, 2018) or a combination of two of these treatment modalities (Arnold et al., 2005; Strosberg et al., 2017). Detailed study characteristics are presented in Table 2.

### 3.1 Risk of bias assessment outcomes

Only one RCT was considered having a “low” risk of bias (Caplin et al., 2014). All other RCT’s had “unclear” or “high” risk of bias associated with one or more domains in the Cochrane Risk of Bias tool, shown in Figure 2 (Arnold et al., 2005; Raymond et al., 2011; Rinke et al., 2009; Strosberg et al., 2017). Five cohort studies were awarded a “moderate” quality rating (5 stars) (Ducreux et al., 2014; Mitry et al., 2014; Pavel, Unger, et al., 2016; Ramage et al., 2019; Strosberg et al., 2017).

---

**FIGURE 1** Prisma flow diagram of study identification and selection process
### SSA therapies

| First author | Year | Type of study | Study treatment | Number of patients | Included tumour types | Included tumour grades | Outcomes reported |
|--------------|------|---------------|-----------------|--------------------|-----------------------|-----------------------|-------------------|
| Rinke        | 2009 | Phase IIIb RCT PROMID trial | Octreotide LAR vs. placebo | 42 vs. 43 | All midgut NETs | Ki-67 ≤ 2%: 97.6% vs. 93.0% | PFS, OS, tumour response, adverse events, global health status/QOLb |
| Caplin       | 2014 | Phase IIIb RCT CLARINET trial | Lanreotide autogel vs. placebo | 101 vs. 103 | Pancreas (91), midgut (73), hindgut (14), unknown (26) | Ki-67 ≤ 2%: 68% vs. 70% | PFS, OS, adverse events, all EORTC QLQ-C30 and GINET21 scales c |
| Phan         | 2016 | Phase IIIb RCT CLARINET trial | Lanreotide autogel vs. placebo | 101 vs. 103 | Reported by Caplin et al., 2014 | | Tumour response |
| Rinke        | 2017 | Phase IIIb RCT PROMID trial | Octreotide LAR vs. placebo | 42 vs. 43 | Reported by Rinke et al., 2009 | | Long-term PFS, long-term OS |
| Rinke        | 2019 | Phase IIIb RCT PROMID trial (post-hoc analysis) | Octreotide LAR vs. placebo | 42 vs. 43 | Reported by Rinke et al., 2009 | | Time to definitive deterioration (all EORTC QLQ-C30 scales) |

### PRRT therapies

| First author | Year | Type of study | Study treatment | Number of patients | Included tumour types | Included tumour grades | Outcomes reported |
|--------------|------|---------------|-----------------|--------------------|-----------------------|-----------------------|-------------------|
| Cwikla       | 2010 | Phase II | ⁹⁰Y-DOTATATE | 60 | Foregut (25), midgut (29), unknown (6) | Grades 1 and 2 (proportions unknown) | PFS, OS, tumour response, adverse events, EORTC QLQ-C30 and GINET items: Diarrhoea, flushingd |
| Delpassand   | 2014 | Phase II | ¹⁷⁷Lu-DOTATATE | 37 | Pancreas (14), small bowel (12), rectum (3), large bowel (1), unknown (7) | Grades 1 and 2 (proportions unknown) | PFS, tumour response, adverse events, EORTC QLQ-C30 items: Overall QOL, stamina for daily activities, diarrhoea |

### SSA combination therapies

| Author | Year | Type of study | Study treatment | Number of patients | Included tumour types | Included tumour grades | Outcomes reported |
|--------|------|---------------|-----------------|--------------------|-----------------------|-----------------------|-------------------|
| Arnold | 2005 | RCT | Octreotide vs. octreotide and INFa | 51 vs. 54 | Foregut (pancreas) (40), midgut (45), unknown (20) | Ki-67 ≤ 2%: 55.2% Ki-67 > 2%: 44.8% (67 evaluable patients at baseline) | PFS, OS, tumour response, adverse events, global health status/QOLb |

(Continues)
| SSA therapies | First author | Year | Type of study | Study treatment | Number of patients | Included tumour types | Included tumour grades | Outcomes reported |
|---------------|--------------|------|---------------|-----------------|--------------------|----------------------|----------------------|-------------------|
|               | Strosberg    | 2017 | Phase III RCT NETTER-1 trial | $^{177}$Lu-DOTATATE and octreotide LAR vs. high dose octreotide LAR | 116 vs. 113 | Ileum (168), small intestine, not otherwise specified (23), midgut not otherwise specified (16), jejunum (15), right colon (4), appendix (3) | Grade 1: 66% vs. 72% Grade 2: 35% vs. 28% | PFS, OS, tumour response*, adverse events |
|               | Strosberg    | 2018 | Phase III RCT NETTER-1 trial | $^{177}$Lu-DOTATATE and octreotide LAR vs. high dose octreotide LAR | 117 vs. 114 | Ileum (168), small intestine, not otherwise specified (23), midgut not otherwise specified (16), jejunum (15), right colon (4), appendix (3) | Unknown for larger cohort* | Time to deterioration (all EORTC QLQ-C30 scales) |
|               | Strosberg    | 2020 | Phase III RCT NETTER-1 trial | $^{177}$Lu-DOTATATE and octreotide LAR vs. high dose octreotide LAR | 117 vs. 114 | Ileum (168), small intestine, not otherwise specified (23), midgut not otherwise specified (16), jejunum (15), right colon (4), appendix (3) | Unknown for larger cohort* | PFS, HRQoL, hepatic toxicity and live lesion shrinkage by extent of liver tumour burden |

| Chemotherapies | First author | Year | Type of study | Study treatment | Number of patients | Included tumour types | Included tumour grades | Outcomes reported |
|----------------|--------------|------|---------------|-----------------|--------------------|----------------------|----------------------|-------------------|
|               | Mitry        | 2014 | Phase II BETTER trial | Bevacizumab and capecitabine | 49 | Small intestine (40), caecum (3), stomach (2) | Ki-67 ≤ 2%: 35% Ki-67 < 15%: 64% Missing: 1% | PFS, OS, tumour response, adverse events, global health status/QOL |
|               | Ducreux      | 2014 | Phase II BETTER trial | Bevacizumab and 5-FU/streptozocin | 34 | Pancreas (33), duodenopancreatic tumour (1) | Grade 1: 25% Grade 2: 75% | PFS, OS, tumour response, adverse events, global health status/QOL |

| Targeted therapies | First author | Year | Type of study | Study treatment | Number of patients | Included tumour types | Included tumour grades | Outcomes reported |
|--------------------|--------------|------|---------------|-----------------|--------------------|----------------------|----------------------|-------------------|
|                    | Raymond      | 2011 | Phase III RCT | Sunitinib vs. placebo | 86 vs. 85 | All pancreas | Ki-67 ≤ 2%: 19% vs. 17% Ki-67 > 2%–10%: 58% vs. 67% Ki-67 > 10%: 22% vs. 17% | PFS, OS, tumour response, adverse events, all EORTC QLQ-C30 scales |
|                    | Vinik        | 2016 | Phase III RCT (post-hoc analysis) | Sunitinib vs. placebo | 73 vs. 71 (from Raymond 2011) | All pancreas | Proportions unknown for smaller cohort* | Time to deterioration (all EORTC QLQ-C30 scales) |
**TABLE 2 (Continued)**

| First author | Year | Type of study | Study treatment | Number of patients | Included tumour types | Included tumour grades | Outcomes reported |
|--------------|------|---------------|------------------|--------------------|-----------------------|-----------------------|-------------------|
| Pavel        | 2016 | Phase III b   | Everolimus       | 126                | All pancreas          | Well differentiated: 64.3% | PFS, tumour response, adverse events, all EORTC QLQ-C30 and GINET21 scales<sup>a</sup> |
| Faivre       | 2017 | Phase III RCT | Sunitinib vs. placebo | 86 vs. 85         | Published by Raymond et al. (2011) | Long-term PFS, long-term OS |
| Raymond      | 2018 | Phase IV     | Sunitinib        | 106                | All pancreas          | All well-differentiated | PFS, OS, tumour response, adverse events, all EORTC QLQ-C30 and GINET21 scales |
| Raymond      | 2018 | Phase IV     | Sunitinib        | 106                | All pancreas          | All well-differentiated | OS, tumour response, adverse events |
| Ramage       | 2019 | Phase IV OBLIQUE study | Everolimus | 48 (safety)/46 (full analysis) | All pancreas | Grade 1: 33% Grade 2: 52% Grade 3: 0.02%<sup>b</sup> Unknown: 13%<sup>c</sup> | PFS, OS, tumour response, adverse events, all EORTC QLQ-C30 and GINET21 scales |

**Abbreviations:** SSA, somatostatin analogues; PRRT, peptide receptor radionuclide therapy; RCT, randomised-controlled trial; PFS, progression-free survival; OS, overall survival; HRQoL, health-related quality of life; QOL, quality of life.

<sup>a</sup>All included tumours are described as well-differentiated.

<sup>b</sup>Reported as “global QOL” and scored on 0 (worst) to 100 (best) scale and therefore assumed to represent global health status/QOL scale.

<sup>c</sup>Baseline scores for quality of life scales/items not reported.

<sup>d</sup>Scores for scales/items not reported.

<sup>e</sup>Proportion of patients with stable disease not reported.

<sup>f</sup>No description of additional two patients included in cohort compared to Strosberg et al. (2017) (n = 229).

<sup>g</sup>Inclusion of ≤1% of poorly differentiated NETs was accepted due to the assumption of negligible interference.
Six studies measured HRQoL using the EORTC QLQ-C30 in combination with the NEN symptom-specific QLQ-GINET21 module (Caplin et al., 2014; Cwikla et al., 2010; Pavel, Unger, et al., 2016; Ramage et al., 2019; Raymond et al., 2018; Strosberg et al., 2018), and six studies used only the EORTC QLQ-C30 questionnaire (Arnold et al., 2005; Delpassand et al., 2014; Duceux et al., 2014; Mitry et al., 2014; Raymond et al., 2011; Rinke et al., 2009). Four studies reported complete data on the global health status/QOL, functional and symptom scales (Ramage et al., 2019; Raymond et al., 2018; Rinke et al., 2019; Vinik et al., 2016), one study reported change scores for all scales without providing baseline data (Caplin et al., 2014), and one study published results of a time to deterioration (TTD) analysis for all scales without providing change from baseline or final visit scores (Strosberg et al., 2018). Two studies reported results of all scales without providing supporting data (Pavel, Unger, et al., 2016; Raymond et al., 2011). Furthermore, two studies reported quantitative results of the global health status/QOL scale alone (Arnold et al., 2005; Mitry et al., 2014), one study described results of this scale alone without providing data (Ducreux et al., 2014) and two reported qualitative results of individual items (Cwikla et al., 2010; Delpassand et al., 2014). All included studies reported results on median PFS, and 10 studies on OS (Arnold et al., 2005; Caplin et al., 2014; Cwikla et al., 2010; Duceux et al., 2014; Mitry et al., 2014; Ramage et al., 2019; Raymond et al., 2011, 2018; Rinke et al., 2009; Strosberg et al., 2017). Overall response rate was reported in all but one study (Ramage et al., 2019), and clinical benefit was reported in 10 studies (Arnold et al., 2005; Caplin et al., 2014; Cwikla et al., 2010; Delpassand et al., 2014; Duceux et al., 2014; Mitry et al., 2014; Pavel, Unger, et al., 2016; Raymond et al., 2011, 2018; Rinke et al., 2009). All studies reported on AEs: two using the WHO scale (Arnold et al., 2005; Cwikla et al., 2010), two using the Medical Dictionary for Regulatory Activities (Caplin et al., 2014; Ramage et al., 2019), one using the WHO criteria or the National Cancer Institute Common Toxicity Criteria (version 2.0) (Rinke et al., 2009), four using the Common Terminology Criteria for Adverse events version 3.0 (Duceux et al., 2014; Mitry et al., 2014; Raymond et al., 2011, 2018), two using version 4.03 (Delpassand et al., 2014; Strosberg et al., 2017) and one using version 4.0 (Pavel, Unger, et al., 2016). Detailed results on PFS, OS, tumour response rates and AEs are presented in Table 4.

### 3.3 SSA therapy outcomes

Five publications on two randomised and placebo-controlled trials reported solely on SSA therapies: the CLARINET trial on lanreotide (Caplin et al., 2014; Phan et al., 2016) and the PROMID trial on octreotide LAR (Rinke et al., 2009, 2017, 2019).

A meta-analysis revealed no statistically significant mean difference in global health status/QOL between intervention and
The proportion of grade 3–4 AEs were similar in intervention and placebo arms. Both trials reported positive effects on disease progression as median PFS was significantly longer in both lanreotide and octreotide arms when compared to placebo. However, neither treatment resulted in a longer median OS when compared to placebo (Table 4).

Tumour response outcomes, including the octreotide and octreotide LAR control groups from the combination studies by Arnold et al. (2005) and Strosberg et al. (2017), respectively, were pooled (\(I^2 = 0\%\)) (Phan et al., 2016; Rinke et al., 2009). Pooled ORR was 2% (95% CI: 1–5%), Figure 4a. Due to statistical heterogeneity, a meta-analysis on clinical benefit rates could not be performed (\(I^2 = 93\%\)). Individual CB rates after SSA therapy are shown in Figure S2a. Strosberg et al. (2017) did not publish data on CB.

### 3.4 PRRT outcomes

Two cohort studies reported on the PRRT therapies \( ^{90}\text{Y-DOTATATE} \) (Cwikla et al., 2010) and \( ^{177}\text{Lu-DOTATATE} \) (Delpassand et al., 2014), respectively. Delpassand et al. (2014) described a significant improvement in overall quality of life from baseline (\( p < 0.05 \)), as well as a significant improvement in stamina for daily activities and diarrhoea after \( ^{177}\text{Lu-DOTATATE} \) therapy. (Cwikla et al., 2010) found \( ^{90}\text{Y-DOTATATE} \) therapy to reduce diarrhoea in 53%, abdominal pain in 63% and flushing in 75% of patients (Table 5).

Neither study reported overall rates of grade 3–4 AEs. However, hematologic AEs were the most common grade 3–4 AEs in both studies and occurred in 33% and 12.5% of patients under \( ^{90}\text{Y-DOTATATE} \) and \( ^{177}\text{Lu-DOTATATE} \) therapies, respectively. Both studies reported similar median PFS results: 17 months under \( ^{90}\text{Y-DOTATATE} \) therapy and 16.1 months under \( ^{177}\text{Lu-DOTATATE} \). Median OS was 22 months after \( ^{90}\text{Y-DOTATATE} \) therapy (Table 4).

The pooled ORR was 33% (95% CI: 24–45%) (Figure 4b). Due to heterogeneity, a meta-analysis on clinical benefit could not be performed (\(I^2 = 76\%\)). Individually, CB rates are presented in Figure S2b.

### 3.5 SSA combination therapy outcomes

Four studies on two populations published results on SSA combinations (Arnold et al., 2005; Strosberg et al., 2017, 2018; Strosberg et al., 2020). Results of the NETTER-1 trial, a RCT on \( ^{177}\text{Lu-DOTATATE} \) and octreotide LAR combination treatment versus high dose octreotide LAR alone, were published in three separate studies (Strosberg et al., 2017, 2018, 2020). TTD, defined as the time to a deterioration of \( \geq 10 \) points, and TDD were significantly improved in the \( ^{177}\text{Lu-DOTATATE}/\text{octreotide} \) arm in the global health status/QOL, physical functioning, role functioning, diarrhoea, pain, body image and disease-related worries scales (Table 5). TDD was further delayed in the emotional functioning, social functioning, insomnia, appetite loss, constipation, gastrointestinal symptoms and treatment-related symptoms scales. However, grade 3–4 AEs occurred more frequently in the \( ^{177}\text{Lu-DOTATATE}/\text{octreotide} \) arm, compared to the octreotide LAR arm (41% vs. 33%; \( p < 0.05 \)).
### Survival, response, and adverse events results

#### SSA therapies

| Study                  | Study treatment                                      | PFS (months) | OS (months) | ORR (%) | CB (%) | G3/4 AEs (%) |
|------------------------|------------------------------------------------------|--------------|-------------|---------|--------|--------------|
| Rinke 2009 2017 2019   | Octreotide LAR vs. placebo                          | 14.3 vs. 6.0*** | 84.3 vs. 83.7 NS | 2.4 vs. 2.3 | 69.0 vs. 39.5 | 26 vs. 23 NS |
| Caplin 2014 Phan 2016  | Lanreotide autogel vs. placebo                      | Not reached vs. 18*** | Not reached | 2.0 vs. 0.0 | 66.3 vs. 42.7 | 25 vs. 32 NS |

#### PRRT

| Study                  | Study treatment                                      | PFS (months) | OS (months) | ORR (%) | CB (%) | G3/4 AEs (%) |
|------------------------|------------------------------------------------------|--------------|-------------|---------|--------|--------------|
| Cwikla 2010            | 90Y-DOTATATE                                         | 17           | 22          | 24.9    | 90.7   | -            |
| Delpassand 2014        | 177Lu-DOTATATE                                       | 16.1         | -           | 31.3    | 71.9   | -            |

#### SSA combination therapies

| Study                  | Study treatment                                      | PFS (months) | OS (months) | ORR (%) | CB (%) | G3/4 AEs (%) |
|------------------------|------------------------------------------------------|--------------|-------------|---------|--------|--------------|
| Arnold 2005            | Octreotide vs. octreotide and INFa                   | 6 vs. 6      | 32 vs. 54 NS | 2.0 vs. 9.3 | 17.7 vs. 24.1 | -            |
| Strosberg 2017 2018    | 177Lu-DOTATATE and octreotide LAR vs. high dose octreotide LAR | Not reached vs. 8.4*** | Not reached | 18 vs. 3* | -      | 41 vs. 33*   |

#### Chemotherapies

| Study                  | Study treatment                                      | PFS (months) | OS (months) | ORR (%) | CB (%) | G3/4 AEs (%) |
|------------------------|------------------------------------------------------|--------------|-------------|---------|--------|--------------|
| Mitry 2014             | Bevacizumab and capecitabine                         | 23.4         | Not reached | 18.4    | 87.8   | 84           |
| Ducreux 2014           | Bevacizumab and 5-FU/streptozocin                    | 23.7         | Not reached | 55.9    | 100    | 65           |

#### Targeted therapies

| Study                  | Study treatment                                      | PFS (months) | OS (months) | ORR (%) | CB (%) | G3/4 AEs (%) |
|------------------------|------------------------------------------------------|--------------|-------------|---------|--------|--------------|
| Raymond 2011 Vinik 2016 Faivre 2016 | Sunitinib malate vs. placebo                           | 11.4 vs. 5.5*** | 38.6 vs. 29.1 NS | 9.3 vs. 0.0 | 72.1 vs. 60.0 | -            |
| Pavel 2016             | Everolimus                                           | 7.6          | -           | 1.6     | 60.3   | 41.2         |
| Raymond 2018 Raymond 2020 | Sunitinib                                          | 13.2         | 54.1        | 24.5/21.7†† | 89.6§§  | 50           |
| Ramage 2019            | Everolimus                                           | 25.1‡‡       | Not reached | -       | -      | 7.5          |

**Abbreviations:** SSA, somatostatin analogues; PRRT, peptide receptor radionuclide therapy; PFS, progression-free survival; OS, overall survival; ORR, overall response rate; CB, clinical benefit; G3–4 AE, grade 3–4 adverse events; TD, treatment discontinuations due to adverse events; NS, not significant; NR, significance not reported; S, reported as “significant”, but statistical significance unclear.

- All baseline global health values are stated as mean ± standard error, unless otherwise stated.
- Change in global health values are stated as mean change, mean change ± standard error or mean change (95% CI).
- “Quit voluntarily” (unclear whether AE related).
- 16% of patients discontinued bevacizumab and 24% of patients discontinued capecitabine due to AEs.
- HRQoL results were not presented for the whole population.
- Disease progression assessed by investigator based on clinical and/or radiological findings.
- ORR updated by independent assessment. Updated data not given for clinical benefit.
- ORR was 21.7% in the independent third-party assessment; data only given in percentage.

* p < 0.05.
** p < 0.01.
*** p < 0.001.
**** p < 0.0001.
| SSA therapies | Study | Most common G3/4 AEs intervention arm (%) | Most common G3/4 AEs control arm (%) | TD (%) | AE-related deaths (%) |
|---------------|-------|------------------------------------------|-------------------------------------|--------|-----------------------|
|               | Rinke 2009 2017 2019 | Fatigue and fever 19; GI tract symptoms 14 | Fatigue and fever 5; GI tract symptoms 19 | 11.9 vs. 0.0 | 0 vs. 0 |
|               | Caplin 2014 Phan 2016 | GI disorders 16; infections 11 | GI disorders 19 infections 8 | 3 vs. 3 | - |

| PRRT          | Study | Most common G3/4 AEs intervention arm (%) | Most common G3/4 AEs control arm (%) | TD (%) | AE-related deaths (%) |
|---------------|-------|------------------------------------------|-------------------------------------|--------|-----------------------|
|               | Cwikla 2010 | Hematologic 33; renal 3 | - | 13 | - |
|               | Delpassand 2014 | Hematologic 12.5; hepatic 9.4 | - | 13.5 § | 0 |

| SSA combination therapies | Study | Most common G3/4 AEs intervention arm (%) | Most common G3/4 AEs control arm (%) | TD (%) | AE-related deaths (%) |
|---------------------------|-------|------------------------------------------|-------------------------------------|--------|-----------------------|
|                           | Arnold 2005 | - | - | 3.9 vs. 20.4 | 0 vs. 0 |
|                           | Strosberg 2017 2018 | Lymphopenia 9; vomiting 7; | Abdominal pain 5; decreased appetite 3 | 5 vs. 0 | 0 |

| Chemotherapies         | Study | Most common G3/4 AEs intervention arm (%) | Most common G3/4 AEs control arm (%) | TD (%) | AE-related deaths (%) |
|------------------------|-------|------------------------------------------|-------------------------------------|--------|-----------------------|
|                        | Mitry 2014 | Hypertension 31. diarrhea 14 | - | 16/24 | 4 |
|                        | Ducreux 2014 | Hypertension 21; abdominal pain 12 | - | 47 | 3 |

| Targeted therapies | Study | Most common G3/4 AEs intervention arm (%) | Most common G3/4 AEs control arm (%) | TD (%) | AE-related deaths (%) |
|-------------------|-------|------------------------------------------|-------------------------------------|--------|-----------------------|
|                   | Raymond 2011 Vinik 2016 Faivre 2016 | Neutropenia 12; hypertension 10 | Abdominal pain 10; back pain 8 | 17 vs. 8 | 1 vs. 1 |
|                   | Pavel 2016 | Hyperglycemia 6.5; infections 5.7 | - | 17.1 | 0 |
|                   | Raymond 2018 Raymond 2020 | Neutropenia 20.8; thrombocytopenia 7.5 | - | 9.4 | 0 |
|                   | Ramage 2019 | Mucosal inflammation 10.4; diarrhoea 4.2 | - | 48 | 0 |

Abbreviations: SSA, somatostatin analogues; PRRT, peptide receptor radionuclide therapy; PFS, progression-free survival; OS: overall survival; ORR, overall response rate; CB, clinical benefit; G3–4 AE, grade 3-4 adverse events; TD, treatment discontinuations due to adverse events; NS, not significant; NR, significance not reported; S, reported as “significant”, but statistical significance unclear.

*All baseline global health values are stated as mean ± standard error, unless otherwise stated.

bChange in global health values are stated as mean change, mean change ± standard error or mean change (95% CI).

c“Quit voluntarily” (unclear whether AE related).

d16% of patients discontinued bevacizumab and 24% of patients discontinued capecitabine due to AEs.

*eHRQoL results were not presented for the whole population.

fDisease progression assessed by investigator based on clinical and/or radiological findings.

gORR updated by independent assessment. Updated data not given for clinical benefit.

hORR was 21.7% in the independent third-party assessment; data only given in percentage.

*p < 0.05. **p < 0.01. ***p < 0.001.

****p < 0.0001.
Grade 3–4 haematological AEs occurred in 13% of patients in the combination arm. Furthermore, the median PFS was significantly longer in the combination arm (not reached in 30 months vs. 8.4 months, \( p < 0.001 \)). Furthermore, in a post-hoc analysis, PFS benefit was not dependent on liver tumour burden (Strosberg et al., 2020). The combination of 177Lu-DOTATATE and octreotide LAR resulted in an ORR of 18% (95% CI: 11–27%), significantly higher than in the octreotide LAR arm (\( p < 0.001 \)) and the pooled ORR of SSA therapies, but lower than the pooled ORR of PRRT monotherapies. Results on clinical benefit were not reported (Table 4).

A randomised trial, comparing octreotide combined with IFNa to octreotide monotherapy, found a significant difference in global health status/QOL, favouring octreotide monotherapy (\( p < 0.01 \)) (Arnold et al., 2005). Additionally, severe AEs occurred more frequently in the octreotide/IFNa combination arm compared to the octreotide arm (statistical significance not reported). Furthermore, neither PFS nor OS differed significantly between octreotide and octreotide/IFNa arms. Arnold et al. reported an ORR of 9% (95% CI: 3–20%) in the octreotide/IFNa combination arm, not significantly differing from the pooled ORR of SSA therapies.

### 3.6 Chemotherapy outcomes

Two included cohort studies reported on chemotherapy modalities: one on the combination of bevacizumab with 5-fluorouracil and streptozocin (Ducreux et al., 2014), and the other on the combination treatment of bevacizumab and capecitabine (Mitry et al., 2014).

Both studies reported non-significant changes in the global health status/QOL scale (Table 5). Grade 3–4 AEs were reported in 84% of patients during bevacizumab and capecitabine treatment and 65% of patients during bevacizumab combined with 5-FU and streptozocin treatment. AE-related deaths occurred in 3% and 4% of patients receiving bevacizumab/5-FU/streptozocin and bevacizumab/capecitabine, respectively. Furthermore, PFS was similar (both 23 months), while OS was not reached in either study (Table 4).

Due to heterogeneity, results on overall response rates could not be pooled (\( I^2 = 91 \% \)). Individual ORR results are shown in Figure S1a. The pooled CB rate was 94% (95% CI: 65–99%) for the chemotherapy studies (Figure 5).

### 3.7 Targeted therapies outcomes

Seven studies on four populations with pancreatic NENs reported on targeted therapies: three studies published results of a randomised, placebo-controlled trial on sunitinib treatment (Raymond et al., 2011; Faivre et al., 2017; Vinik et al., 2016), one phase three trial reported on everolimus treatment (Pavel, Unger, et al., 2016) and two phase four trials evaluated the efficacy and safety of sunitinib (Fazio et al., 2021; Raymond et al., 2018) and everolimus (Ramage et al., 2019), respectively.

In the RCT, global health status/QOL did not differ significantly between sunitinib and placebo arms (Raymond et al., 2011). However, sunitinib treatment resulted in clinically worsened diarrhoea (\( p < 0.001 \)) and statistically worsened insomnia (<10 points), when compared to placebo. Significantly delayed TTD in global health status/QOL, emotional functioning, physical functioning and constipation were found in the sunitinib arm when compared to placebo arm (Vinik et al., 2016). Similarly, stable global health status/QOL and clinically worsened diarrhoea was reported by the phase four trial on sunitinib (Raymond et al., 2018) (Table 5). Summary scores did not show clinically significant changes in any of the studies (Table 6).

Grade 3–4 AEs were more common in the sunitinib arm than in the placebo arm, and median PFS was significantly longer in the sunitinib arm (11.4 months vs. 5.5 months, \( p < 0.001 \)) (Raymond et al., 2011). OS was similar in both groups (38.6 months vs. 29.1 months) (Faivre et al., 2017). PFS was comparable in the phase four trial, median OS was 54.1 months and grade 3–4 AEs occurred in 50% of patients (Vinik et al., 2016). Similarly, stable global health status/QOL and clinically worsened diarrhoea was reported by the phase four trial on sunitinib (Raymond et al., 2018) (Table 5). Summary scores did not show clinically significant changes in any of the studies (Table 6).

Both studies on everolimus reported stable global health status/QOL scores (Pavel, Unger, et al., 2016; Ramage et al., 2019). Ramage et al. further reported some clinically significant changes in the physical functioning, dyspnea, constipation, disease-related worries and social functioning scales during follow-up, but none were statistically significant 6 months after treatment (Table 5). Similarly, summary scores remained stable (Table 6). Grade 3–4 AEs occurred in 41.2% and 7.5% of patients in the studies of Pavel et al. and Ramage et al., respectively. The latter reported more treatment discontinuations due to AEs than the former. Furthermore, Pavel, Unger, et al. (2016) reported the shortest PFS of 7.6 months, while Ramage et al. (2019)
### TABLE 5  Health-related quality of life results

| SSA therapy | Study | Study treatment | Timepoints of HRQoL measurements | Δ global health status/QOL | Δ functional scales | Δ symptom scales | Δ GINET 21 scales | Time to deterioration (months) |
|-------------|-------|-----------------|---------------------------------|---------------------------|-------------------|-----------------|-----------------|-------------------------------|
| Rinke et al. (2009, 2019) | Octreotide LAR vs. placebo | Baseline and at 12-week intervals until progression (up to 22 months) | 6 months: 0.0 ± 18.5 vs. −2.1 ± 15 NS | All NCS/NS | Fatigue −1.1 vs. +9.7* Pain −8.4 vs. +4.1* Insomnia −7.6 vs. +7.3* Others NCS/NS | - | Definitive deterioration: Fatigue 18.5 vs. 6.8*** Pain NR vs. 18.2* Insomnia NR vs. 16.4** Others NS |
| Caplin et al. (2014) | Lanreotide autogel vs. placebo | Weeks 1, 12, 24, 36, 48, 72, and 96 | −5.2 ± 3.7 vs. −4.9 ± 3.7 NS | All NCS/NS | All NCS/NS | Weight gain +14.6 vs. +12.8 NS All others NCS/NS | - |
| PRRT | | | | | | | | |
| Cwikla et al. (2010) | 90 Y-DOTATATE | Baseline and 4–6 weeks after each cycle. | | | | | | Decrease in flushing (9/11 patients) SNRa |
| Delpassand et al. (2014) | 177Lu-DOTATATE | Baseline, after treatment and at 3-month follow-up. | Significant improvement of “overall QOL”** a | Significantly improved stamina for daily activities SNRb | | | | |
| SSA combination therapies | | | | | | | | |
| Arnold et al. (2005) | Octreotide vs. octreotide and INFa | Baseline and 3 months after start of treatment. | “Global QOL”: +11.4 ± 18.6 vs. −6.4 ± 18.6”** | | | | | |
| Strosberg (2018) | 177Lu-DOTATATE and octreotide LAR vs. high dose octreotide LAR | Baseline and every 12 weeks until 72 weeks or progression. | | | | | | Global health status: 28.8 vs. 6.1 (HR0.41, 95% CI 0.24–0.69***); Physical functioning: 25.2 vs. 11.5 (HR 0.52, 95% CI 0.30–0.89*); Diarrhoea: HR 0.47 (95% CI 0.26–0.85)* Pain: HR 0.57 (95% CI 0.34–0.94)* |

(Continues)
| SSA therapy |
|-------------|
| Study | Study treatment | Timepoints of HRQoL measurements | Δ global health status/QOL | Δ functional scales | Δ symptom scales | Δ GINET 21 scales | Time to deterioration (months) |
| Mitry et al. (2014) | Bevacizumab and capecitabine | Baseline and every 3 months | 6 months: – 4 NS | - | - | - | - |
| Ducreux et al. (2014) | Bevacizumab and 5-FU/streptozocin | At 0, 3, 6 and 12 months | NS | - | - | - | - |
| Targeted therapies |
| Study | Study treatment | Timepoints of HRQoL measurements | Δ global health status/QOL | Δ functional scales | Δ symptom scales | Δ GINET 21 scales | Time to deterioration (months) |
| Pavel (2016) | Everolimus | Baseline and cycles 1, 2, and 3 (28-day intervals) and then once every three cycles (84-day intervals) until the end of treatment | 3.9 ± 21.0 SNR | All NCS | All NCS | All NCS | - |

**Chemotherapies**

**Mitry et al. (2014)**

- Bevacizumab and capecitabine

- At 0, 3, 6 and 12 months

- Body image: HR 0.43 (95% CI 0.23–0.80)**

- Disease-related worries:
  - HR 0.57 (95% CI 0.35–0.91)*;
  - Fatigue HR 0.6 (95% CI 0.40–0.96)*

- Others NS

**Ducreux et al. (2014)**

- Bevacizumab and 5-FU/streptozocin

- At 0, 3, 6 and 12 months

- Others NS

**Targeted therapies**

**Raymond et al. (2011); Vinik et al. (2016)**

- Sunitinib malate vs. placebo

- Baseline and every 4 weeks (1 cycle), Total of 10 cycles.

- 5 cycles: Role 5.1 vs. 1.7 NS

- 10 cycles: Role 13.2 vs. 5.3 NS

- 10 cycles: Role 13.4 vs. 8.1 NS

- Others NCS/NS

- Diarrhoea 18.6 vs. 4.1***

- Fatigue 10.3 vs. 2.7 NS

- Others NCS/NS

- Global health status: 5.5 vs. 3.5*

- Emotional functioning: 7.5 vs. 4.7**

- Physical functioning: 5.5 vs. 3.5*

- Constipation: 8.3 vs. 3.9***

- Sensitivity analyses (PFS and death controlled)

- Accelerated TTD in diarrhoea and dyspnea

**Pavel (2016)**

- Baseline and cycles 1, 2, and 3 (28-day intervals) and then once every three cycles (84-day intervals) until the end of treatment

- Global health status: 5.5 ± 21.0 SNR

- Emotional functioning: 7.5 ± 4.7**

- Physical functioning: 5.5 ± 3.5*

- Constipation: 8.3 ± 3.9***

- Sensitivity analyses (PFS and death controlled): Accelerated TTD in diarrhoea and dyspnea

**Note:** All NCS indicates no statistically significant change.
### TABLE 5 (Continued)

| Study             | SSA therapy | Study treatment | Timepoints of HRQoL measures                                                                 | Δ global health status/QOL | Δ functional scales | Δ symptom scales | Δ GINET 21 scales | Time to deterioration (months) |
|-------------------|-------------|-----------------|------------------------------------------------------------------------------------------------|----------------------------|-------------------|-----------------|-------------------|-------------------------------|
| Raymond et al. (2018) | Sunitinib | Baseline, first day of each cycle, until end of treatment or withdrawal (max 10 cycles) | Treatment naïve (TN): −6.0 ± 19.0 SNR, Previously treated (PT): −2.2 ± 17.6 SNR | Social: −11.6 ± 26.3 (PT) SNR | Others NCS | Diarrhoea: +13.3 ± 27.1 (TN) SNR, +17.4 ± 31.6 (PT) SNR | Others NCS | +11.1 ± 29.2 (PT) SNR; sexual function −12.1 ± 34.2 (PT) SNR | Others NCS |
| Ramage et al. (2019) | Everolimus | Baseline, 1, 2, 3, 4, 5 and 6 months following everolimus initiation. | −1.9 (95% CI: −10.9 to 7.0) NS | Month 3: Physical −8.8 (95% CI: −15.1 to −2.5) NS | Others NCS/NS | Month 3: Dyspnea +12 (95% CI 1.9–22.2) NS | Others NCS/NS | Month 1: Disease-related worries −11.5 (95% CI −19.1 to −3.9) | Others NCS |

**Note:** Global health status/QOL scores presented regardless of significance, for other scales clinical and statistically significant changes presented.

**Abbreviations:** SSA, somatostatin analogues; PRRT, peptide receptor radionuclide therapy; HRQoL, health-related quality of life; QOL, quality of life; Δ, change in score from baseline to last post-baseline visit or end of treatment, unless otherwise stated; TDD, time to definitive deterioration; TTD, time to deterioration; NR, not reached; HR, hazard ratio; CI, confidence interval; NS, not statistically significant (p > 0.05); SNR, statistical significance not reported; NCS, not clinically significant (<10 points).

*Data not given.
* p < 0.05. **p < 0.01. ***p < 0.001.

****p < 0.0001.
TABLE 6  EORTC QLQ-C30 summary scores

| SSA therapy | Study | Study treatment | Baseline | Last measurement |
|-------------|-------|-----------------|----------|------------------|
|             | Rinke et al. (2019) | Octreotide LAR | 75.2     | 75.5             |
|             | Rinke et al. (2019) | Placebo       | 73.1     | 70.8             |
| Targeted therapies | Study | Study treatment | Baseline | Last measurement |
|             | Vinik et al. (2016) | Sunitinib malate | 75.5     | 69.3             |
|             | Vinik et al. (2016) | Placebo       | 73.6     | 71.4             |
|             | Raymond et al. (2018) | Sunitinib (treatment naïve) | 80.5 | 77.0 |
|             | Raymond et al. (2018) | Sunitinib (previously treated) | 78.2 | 77.5 |
|             | Ramage et al. (2019) | Everolimus    | 69.0     | 68.6             |

*Missing baseline score for treatment-related symptoms.

FIGURE 4  Forest plots of pooled ORR results for SSA therapies (a) and PRRT (b)

FIGURE 5  Forest plot of pooled CB results for chemotherapy modalities
reported the longest mean PFS of 25.1 months. OS was not reported by Pavel et al. and not reached in Ramage et al. (2019) (Table 4).

Three studies reported on ORR and CB (Pavel, Unger, et al., 2016; Raymond et al., 2011, 2018). Due to heterogeneity, meta-analyses could not be performed ($i^2 = 90\%$ for ORR and $i^2 = 91\%$ for CB). Individual ORR and CB results are presented in Figures S1b and S2c, respectively.

### 3.8 | Overall evidence quality

The overall quality of evidence was graded low to very low for all outcomes using the GRADE approach (Table S1). Evidence levels were mainly downgraded due to poor HRQoL outcome reporting, a lack of RCTs and small study populations.

### 3.9 | Practical guide

Table 7 summarises the clinical outcomes for all treatments in this current review. Shared decision-making is supported with these data; treatment decisions can, for example, be focused on improving HRQoL (PRRT, SSA and PRRT, SSA and IFNa or sunitinib) or more on disease control (SSA, PRRT, chemotherapy and targeted therapies).

#### TABLE 7  Summarised treatment outcomes for shared decision-making

| Treatment          | Time to disease progression | Proportion of patients with tumour response or tumour stabilisation | Proportion of patients with serious adverse events | Most common serious adverse events | Effect on HRQoL |
|--------------------|-----------------------------|-------------------------------------------------------------------|----------------------------------------------------|----------------------------------|-----------------|
| SSA therapy        | Significantly longer compared to placebo. | 66–63% | 25–26% no difference between treatment and placebo. | • Fatigue and fever  
|                    |                             |                     |                                                   | • GI tract symptoms            | Stable HRQoL.  
|                    |                             |                     |                                                   | No difference between treatment and placebo |                 |
| PRRT               | Uncleara | 72–91% | 13–33% | • Hematologic effects | Decrease in symptom burden. |
| SSA and IFNa combination | No difference compared to SSA alone. | 24% | - | - | Significantly improved compared to SSA alone. |
| SSA and PRRT combination | Significantly longer compared to SSA therapy alone. | - | 41% significantly more in combination arm. | • Hematologic effects  
|                    |                             |                     |                                                   | • Vomiting                   | Delayed deterioration in HRQoL in combination arm. |
| Chemotherapy       | Uncleara | 88–100% | 65–84% | • Hypertension  
|                    |                             |                     |                                                   | • GI tract symptoms         | Stable HRQoL. |
| Targeted therapy:  | | | | | |
| Sunitinib          | Significantly longer compared to placebo. | 72–90% | 50% | • Hematologic effects | Decrease in GI symptoms, delayed deterioration in HRQoL. |
| Targeted therapy:  | | | | | |
| Everolimus         | Uncleara | 60% | 7.5–41% | • Infections | Stable HRQoL. |

Note: Serious adverse events are events requiring hospitalisation or invasive intervention, and events with life-threatening consequences.
Abbreviations: SSA, somatostatin analogue; IFNa, interferon alpha; PRRT, peptide radionuclide therapy; HRQoL, health-related quality of life.
*aStudies did not compare treatment to placebo.

The proportion of patients with serious adverse events may also support patients in deciding between treatment options.

### 4 | DISCUSSION

This systematic review and meta-analysis assessed HRQoL, treatment efficacy and AEs in patients with well-differentiated, advanced GEPNENs. All included treatment modalities were associated with stable global health status/QOL scores and disease stabilisation. Serious AEs were most frequently reported during chemotherapy and PRRT. To our knowledge, this systematic review is the first to compare treatments in GEPNEN patients in terms of HRQoL and treatment efficacy in one publication.

Global health status/QOL scores remained stable across all modalities, irrespective of the frequency of serious AEs. Interestingly, the meta-analysis for SSA therapy revealed no significant difference in global health status/QOL between intervention and placebo arms, although SSA treatment was associated with improved symptom scores in the PROMID trial and in previous publications (Appetecchia & Baldelli, 2010; Rinke et al., 2009). Acquired drug tolerance negating an initial improvement in HRQoL scores could explain the stable HRQoL found in our analysis (Appetecchia & Baldelli, 2010). Further HRQoL results corresponded to previous...
reporting: PRRT was associated with improved scores in symptom scales in non-placebo-controlled studies (Hirmas et al., 2018), and sunitinib treatment was associated with worsening diarrhoea (Valle et al., 2014). However, HRQoL results did not reflect the frequency of serious AEs reported, as chemotherapy studies reported the highest proportion of serious AEs out of all studies, and PRRT was associated with a high occurrence of grade 3–4 hematologic AEs. It is possible that final HRQoL scores were recorded after successful treatment of these AEs, i.e. after a decrease in AE-related symptom burden. This potential “response shift” was recently highlighted by Watson et al., who suggested TTD and TDD analyses as a potential solution due to the significant results of the NETTER-1 trial in terms of HRQoL (Watson et al., 2020). In contrast, time-to-event analyses do not depend on the number of patients at (the last) follow-up. However, as suggested by Watson et al., more research is needed to establish whether the existing thresholds for clinical significance and definite deterioration are meaningful in GEPNEN patients.

All modalities reported good CB rates, with chemotherapy and PRRT showing promising effects on tumour regression. A previous review and meta-analysis, investigating systemic treatment of advanced well-differentiated pancreatic NENs, found chemotherapy alone or in combination with anti-VEGF to be the best cytoreductive treatment. However, studies on PRRT alone were not included in this review (Pozzari et al., 2018). Even though past reviews have concluded that PRRT shows promising tumour response, SSA remains the first-line treatment option for metastatic GEPNENs as not all patients are eligible to receive PRRT (Carmona-Bayonas et al., 2017; Gulenchyn et al., 2012; Michael et al., 2017; Pasricha et al., 2017). In the present study, SSA was associated with a low ORR in the meta-analysis and moderate CB rates in both RCTs. This is in accordance with a systematic review by Chan et al. who reported a significant rate of disease control, but no disease regression during escalated-dose SSA (Chan et al., 2017). Of note, a systematic review suggested bevacizumab combinations (with mTOR inhibitors and chemotherapy) to be a more effective and tolerable treatment for advanced GEPNENs. In turn, ORR results showed large variation (0–64%) similar to our review (Abdel-Rahman & Fouad, 2015). In the current study, the combination of 177Lu-DOTATATE with octreotide resulted in a low ORR than reported in the other included PRRT studies, and more adverse events than generally reported by SSA studies. Still, a study assessing CB of currently used systemic treatments using scales published by the European and American societies for Oncology (ESMO-MCBS and NHB-ASCO-F) was unable to demonstrate a meaningful CB in any included study on SSA therapy, PRRT, chemotherapy or targeted therapies. Yet, only eight and six trials of 32 included studies were eligible for grading using the NHB-ASCO-F and ESMO-MCBS scores, respectively (de Hosson et al., 2017).

Notably, past systematic reviews have reported either on the effect of treatment on oncological outcomes (Abdel-Rahman & Fouad, 2015; Chan et al., 2017; Pozzari et al., 2018) or on HRQoL (Jimenez-Fonseca et al., 2015; Watson et al., 2020) alone. This illustrates a persistent divide between traditional treatment outcomes and HRQoL reporting. A recent systematic review found that not even half (47%) of phase III oncology trials conducted between 2012 and 2016 included HRQoL as an end point, suggesting that HRQoL is frequently not an outcome of interest (Marandino et al., 2018). Moreover, another systematic review found that just 40% of Food and Drug Administration (FDA) approved, and 58% of European Medicines Agency (EMA) approved oncology therapies published HRQoL outcomes, and that the majority of drugs were approved based on survival outcomes, illustrating that research on therapies that improve HRQoL is lacking (Arciero et al., 2021). These findings are further exemplified in the current review, where 358 articles were excluded at full text review due to a lack of HRQoL outcomes. Survival and HRQoL outcomes may be variably important in treatment related shared decision-making, depending on patient age, health status and future expectations of life (Shrestha et al., 2019). Therefore, both HRQoL and traditional oncological outcomes are necessary for treatment-related shared decision-making. A summary table was designed which may be used to facilitate treatment-related shared decision-making.

It is important to highlight that overall evidence quality of studies included in this review was poor. We found significant heterogeneity, a lack of randomised-controlled trials as well as poor HRQoL reporting, hindering definite conclusions. An earlier systematic review, conducted on the quality of HRQoL reporting in patients with GEPNENs, reported a detailed analysis of the shortcomings in both processing and reporting of HRQoL data (Martini et al., 2016). In our review, notable limitations included inconsistent use of terminology when describing HRQoL outcomes, limited completeness in reporting HRQoL and the lack of randomised-controlled trials focusing on HRQoL. Due to these limitations, only two of the 12 studies could be included in the meta-analysis, which could only be conducted for the global health status/QOL scale due to missing data. Furthermore, HRQoL results were reduced to just the global health status/QOL scale or preselected individual items in five publications on HRQoL. The QLQ-C30 summary score may be more appropriate when summarising HRQoL data (Giesinger et al., 2016). In fact, the summary score was shown to have a strong prognostic value for overall survival in cancer patients (Husson et al., 2020). Neuroendocrine tumour guidelines should advocate the use of these specific questionnaires as well as complete reporting of QoL in every therapeutic study, to enable future comparisons and further meta-analyses (Falconi et al., 2016; Kulke et al., 2010, 2015).

No publications on cytoreductive surgery of the primary tumour were included despite evidence of longer survival after resection of advanced tumours (Capurso et al., 2012; Partelli et al., 2014). Therefore, no conclusions could be drawn on the effectiveness and safety of surgical debulking in advanced disease.

5 | CONCLUSIONS

In summary, SSA therapy, PRRT, chemotherapy and targeted therapies showed stable global HRQoL and benefits for disease stabilisation in patients with well-differentiated GEPNENs.
Unfortunately, high-quality HRQoL reporting was lacking and was the best order of treatment after progression on SSA therapy remains unknown. Subjective experience of health and quality of life prospects may be decisive in treatment-related decision making. With research focusing on combination therapies and reducing tumour-burden, HRQoL should be investigated along with survival outcomes. Standard use of the EORTC QLQ-C30 questionnaire with the QLQ-GINET21 module should be advocated for all studies with GEPNEN patients.

ACKNOWLEDGEMENT
The authors have no acknowledgments to declare.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

FUNDING INFORMATION
The authors did not receive any funding for this project.

ETHICAL STATEMENT
Ethical approval was not required for this study.

AUTHOR CONTRIBUTIONS
All listed authors contributed to this project according the ICMJE criteria for authorship.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Elsa M. Ronde https://orcid.org/0000-0003-4526-351X

REFERENCES
Abdel-Rahman, O., & Fouad, M. (2015). Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): A systematic review of the literature. Journal of Gastroenterology Research and Clinical Oncology, 14(1), 295–305. https://doi.org/10.1007/s00432-014-1757-5

Appetecchia, M., & Baldelli, R. (2010). Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Journal of Experimental & Clinical Cancer Research, 29(1), 19. https://doi.org/10.1186/1756-9966-29-19

Arciero, V., Delos Santos, S., Koshy, L., Rahmadian A., Saluja R., Everest L., Parmar A., Chan K. K. W. (2021). Assessment of Food and Drug Administration—European Medicines Agency-approved systemic oncology therapies and clinically meaningful improvements in quality of life: A systematic review. JAMA Network Open, 4(2), e2033004. https://doi.org/10.1001/jamanetworkopen.2020.33004

Arnold, R., Rinke, A., Kloes, K.-J., Muller, H. H., Wied, M., Zamzow, K., Schmidt, C., Schade-Brittinger, C., Barth, P., Roll, M., Koller, M., Untertal, M., Hiddemann, W., Schmidt-Laubner, M., Pavlova, M., & Arnold, C. N. (2005). Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumours: A randomizedtrial. Clinical Gastroenterology and Hepatology, 3(8), 761–771. https://doi.org/10.1016/s1542-3565(05)00481-7

Beaumont, J. L., Celli, D., Phan, A. T., Choi, S., Liu, Z., & Yao, J. C. (2012). Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas, 41(3), 461–466. https://doi.org/10.1097/MPA.0b013e3182328045

Caplin, M. E., Pavel, M. E., Cwikla, J. B., et al. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumours. The New England Journal of Medicine, 371, 224–233. https://doi.org/10.1056/NEJMoa1316158

Capurso, G., Rinzivillo, M., Bettini, R., Boninsegna, L., Fave, G. D., & Falconi, M. (2012). Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. The British Journal of Surgery, 99(11), 1480–1486. https://doi.org/10.1002/bjs.8842

Carmona-Bayonas, A., Jimenez-Fonseca, P., Custodio, A., et al. (2017). Optimizing Somatostatin analog use in well or moderately differenti- ated gastroenteropancreatic neuroendocrine tumours. Current Oncology Reports, 19(11), 72. https://doi.org/10.1007/s11912-017-0633-2

Chan, D. L., Ferone, D., Albertelli, M., Pavlakis, N., Segelov, E., & Singh, S. (2017). Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETs: A systematic review. Endocrine, 57(3), 366–375. https://doi.org/10.1007/s11202-017-1360-z

Coates, A., Porzsolt, F., & Osoba, D. (1997). Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. European Journal of Cancer, 33(7), 1025–1030. https://doi.org/10.1005/s0059-8049(97)00049-x

Cwikla, J. B., Sankowski, A., Seklecka, N., Buscombe, J. R., Nasiowerska-Gutmejer, A., Jezierski, K. G., Mikolajczak, R., Pawlak, D., Stepien, K., & Walecki, J. (2010). Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETS): A phase II study. Annals of Oncology, 21(4), 787–794. https://doi.org/10.1093/annonc/mdp372

Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017). Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumours in the United States. JAMA Oncology, 3(10), 1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589

Davies, A. H. G., Larsson, G., Ardlill, J., et al. (2006). Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer, 42(4), 477–484. https://doi.org/10.1016/j.ejca.2005.10.025

de Hors, L. D., van Veenendaal, L. M., Schuller, Y., Zandee, W. T., De Herder, W. W., Tisselhaar, M. E. T., Klumper, H. J., & Walenkamp, A. M. E. (2017). Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendo- crine tumours according to ESMO-MCBS and ASCO framework. Annals of Oncology, 28(12), 3022–3027. https://doi.org/10.1093/annonc/mdx547

Delle Fave, G., O’Toole, D., Sundin, A., et al. (2016). ENETS consensus guidelines update for gastro-duodenal neuroendocrine neoplasms. Neuroendocrinology, 103(2), 119–124. https://doi.org/10.1159/000443168

Delpassand, E. S., Samarghandi, A., Mohajeri, A., Wolin, E. M., Hamiditabar, M., Espenan, G. D., Erion, J. L., O’Dorisio, T. M., Kvols, L. K., Simon, J., Wofangfel, R., Camp, A., Krenning, E. P., & Mojtahedi, A. (2014). Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: The first US phase 2 experience. Pancreas, 43(4), 518–525. https://doi.org/10.1097/MPA.0000000000000113

Ducrueux, M., Dahan, L., Smith, D., O’Toole, D., Lepère, C., Dromain, C., Vilgrain, V., Baudin, E., Lombard-Bohas, C., Scoazec, J. Y., Seitz, J. F., Bitoun, L., Koné, S., & Mitry, E. (2014). Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)—a phase II non-randomised trial. European Journal of Cancer, 50(18), 3098–3106. https://doi.org/10.1016/j.ejca.2014.10.002
procarbazine for recurrent glioblastoma multiforme. Journal of Clinical Oncology. 18(7), 1481–1491. https://doi.org/10.1200/jco.2000.18.7.1481

Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144. https://doi.org/10.1200/jco.1998.16.1.139

Partelli, S., Maurizi, A., Tamburrino, D., Baldoni, A., Polenta, V., Crippa, S., & Falcioni, M. (2014). GEP–NETS UPDATE: A review on surgery for gastro-entero-pancreatic neuroendocrine tumors. European Journal of Endocrinology, 171(4), R153–R162. https://doi.org/10.1530/EJE-14-0173

Pasricha, G., Padhi, P., Daboul, N., & Monga, D. K. (2017). Management of metastatic gastroenteropancreatic neuroendocrine tumors (PROMID): A report from the PROMID study group. Journal of Clinical Oncology, 27(28), 4656–4663. https://doi.org/10.1200/JCO.2009.22.8510

Rinke, A., Neary, M. P., Eriksson, J., Hunger, M., Doan, T., Karli, D., & Arnold, R. (2019). Health-related quality of life for long-acting octreotide versus placebo in patients with metastatic midgut neuroendocrine tumors in the phase 3 PROMID trial. Neuroendocrinology, 109(2), 141–151. https://doi.org/10.1159/000499469

Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadat bats, R., Ronicke, E., Gress, T. M., Müller, H. H., Arnold, R., & for the PROMID Study Group. (2017). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival. Neuroendocrinology, 104(1), 26–32. https://doi.org/10.1159/000443612

Schünemann, H., Broek, J., Guyatt, G., & Oxman, A. (2013). GRADE handbook for grading quality of evidence and strength of recommendations. (Updated Oc ed.) The GRADE Working Group. 2013.

Scoring of the QLQ-C30 Summary Score. (2018). Retrieved from https://qol.eortc.org/app/uploads/sites/2/2018/02/scoring_of_the_qlq-c30_summary_score.pdf

Shrestha, A., Martin, C., Burton, M., Walters, S., Collins, K., & Wyld, L. (2019). Quality of life versus length of life considerations in cancer patients: A systematic literature review. Psychooncology, 28(7), 1367–1380. https://doi.org/10.1002/pon.5054

Stiggelbout, A. M., Van der Weijden, T., De Wit, M. P., et al. (2012). Shared decision making: Really putting patients at the centre of healthcare. BMJ, e256. https://doi.org/10.1136/bmj.e256

Strosberg, J., El-Haddad, G., Wolin, E., et al. (2017). Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. The New England Journal of Medicine, 376(2), 125–135. https://doi.org/10.1056/NEJMoa1607427

Strosberg, J., Kunz, P. L., Hendifar, A., et al. (2020). Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: An analysis of the NETTER-1 study. European Journal of Nuclear Medicine and Molecular Imaging, 47(10), 2372–2382. https://doi.org/10.1007/s00259-020-04709-x

Strosberg, J., Wolin, E., Chesen, B., Kulke M., Bushnell D., Caplin M., Baum R. P., Kunz P., Hobday T., Hendifar A., Oberg K., Sienna M. L., Thevenet T., Margiotta I., Ruszniewski P., Krenning E., on behalf of the NETTER-1 Study Group. (2018). Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial. Journal of Clinical Oncology, 36(25), 2578–2584. https://doi.org/10.1200/JCO.2018.78.5865

Swinburn, P., Wang, J., Chandiwana, D., Mansoor, W., & Lloyd, A. (2012). Elicitation of health state utilities in neuroendocrine tumours. Journal of Medical Economics, 15(4), 681–687. https://doi.org/10.3111/13696998.2012.670175

Valle, J. W., Faivre, S., Hubner, R., Grande, E., & Raymond, E. (2014). Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 40(10), 1230–1238. https://doi.org/10.1016/j.ctrv.2014.09.001

Vinik, A., Buttoney, A., Korytowsky, B., Bang, Y. J., Raoul, J. L., Valle, J. W., Metrakos, P., Hörsch, D., Mundabayat, R., Reisman, A., Wang, Z., Chao, R. C., & Raymond, E. (2016). Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: Results from an international phase III trial. Targeted Oncology, 11(6), 815–824. https://doi.org/10.1007/s11523-016-0462-5

Watson, C., Tallentire, C. W., Ramage, J. K., Srinajaskanthan, R., Leeuwenkamp, O. R., & Fountain, D. (2020). Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World Journal of Gastroenterology, 26(25), 3686–3711. https://doi.org/10.3748/wjg.v26.i25.3686
Wells, G., Shea, B., O’Connel, D., et al. (2013). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute.

Yadegarfar, G., Friend, L., Jones, L., et al. (2013). Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. British Journal of Cancer, 108(2), 301–310. https://doi.org/10.1038/bjc.2012.560

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Ronde, E. M., Heidsma, C. M., Eskes, A. M., Schopman, J. E., & Nieveen van Dijkum, E. J. M. (2021). Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. European Journal of Cancer Care, 30(6), e13504. https://doi.org/10.1111/ecc.13504